UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-2730369 (State or Other Jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in Its Charter) WASHINGTON, DC 20549 FORM 10-Q Delaware 81-2730369 (State or Other Jurisdic ...

业绩总结 - 2021年第四季度总收入为8.127亿美元，2021财年总收入为11亿美元[80] - 2021年第四季度Sotrovimab合作收入为8.095亿美元，2021财年为9.172亿美元[80] - 2021年第四季度每股收益（EPS）为基本4.01美元，稀释后3.92美元，2021财年基本4.07美元，稀释后3.96美元[80] - 截至2021年第四季度，流通在外的普通股约为1.31亿股[80] - 截至2021年第四季度，现金及现金等价物为5.253亿美元，2021财年为5.286亿美元[80] 用户数据 - 截至2022年第一季度，sotrovimab已售出约100万剂，其中60万剂交付给美国政府[32] - 公司计划在2022年上半年将sotrovimab的供应量增加至200万剂，2022年下半年将提供更多剂量[32] - 全球约有4.29亿COVID-19病例，死亡人数约为600万[30] - 全球约有3亿人患有慢性乙型肝炎，现有疗法的功能治愈率低于7%[40][41] - 全球约有3800万人感染HIV，且每年新增病例约150万[65][67] 新产品和新技术研发 - 公司正在进行多个组合疗法的开发，以期实现乙型肝炎的功能治愈[43] - 公司在HBV功能治愈开发中扩展了领导地位，启动了三项新的二期组合试验[9] - 公司正在进行针对HIV的新试验，使用新型HCMV疫苗平台[9] - 预计2022年下半年将启动VIR-2482（单克隆抗体）的二期临床试验[70] - 2022年上半年计划分享VIR-1111（T细胞）的额外临床数据[68] - 目前针对HIV的HCMV基础疫苗处于一期临床阶段，未报告安全信号[68] - 公司正在开发广谱抗病毒药物，旨在抵御未来疾病的耐药性[70] 市场扩张 - 公司已在超过40个国家获得sotrovimab的市场批准、临时授权或紧急使用授权[32] 未来展望 - 预计2022年将有更多sotrovimab收入[10] - 流感疫苗的有效性在10%到60%之间，全球每年因流感死亡约50万人[60]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 1-39083 Vir Biotechnology, Inc. (Exact Name of Registrant as Specified in its ...

NIR WHO: World Health Organization; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus A World Without Infectious Disease J P M O R G A N H E A L T H C A R E C O N F E R E N C E J a n u a r y 1 1 , 2 0 2 2 V I R B I O T E C H N O L O G Y , I N C . L E G A L D I S C L A I M E R Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the nearter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) | Delaware | 81-2730369 | | --- | --- | ...

Vir Biotechnology, Inc. A WORLD WITHOUT INFECTIOUS DISEASE H.C. Wainwright 23rd Annual Global Investment Conference September 13, 2021 Legal disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the expected success, cost, and timing of our research and clinical development plans and clinical trials, our goals with respect to the prophyl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) | Delaware | 81-2730369 | | --- | --- | | (St ...

Vir Biotechnology, Inc. EASL ILC 2021 Hepatitis B Data Call A WORLD WITHOUT INFECTIOUS DISEASE June 25, 2021 Legal Disclaimers Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the expected success, cost, and timing of our research and clinical development plans and clinical trials, our goals with respect to the prophylaxis or treatment of COVI ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter) WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39083 Indicate by check mark whether the registran ...